Lord Abbett Health Care R5 (LHCTX)
| Fund Assets | 8.67M |
| Expense Ratio | 0.78% |
| Min. Investment | $0.00 |
| Turnover | 91.00% |
| Dividend (ttm) | 0.08 |
| Dividend Yield | 0.35% |
| Dividend Growth | -23.07% |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 2, 2025 |
| Previous Close | 24.31 |
| YTD Return | 6.90% |
| 1-Year Return | 33.33% |
| 5-Year Return | 26.27% |
| 52-Week Low | 18.22 |
| 52-Week High | 24.58 |
| Beta (5Y) | n/a |
| Holdings | 60 |
| Inception Date | Jul 31, 2019 |
About LHCTX
Lord Abbett Health Care Fund Class R5 is an actively managed mutual fund that focuses on delivering long-term capital growth by investing primarily in equity securities of companies within the health care sector. The fund’s portfolio is diversified across areas such as pharmaceuticals, biotechnology, medical devices, and health care services. Managed by Lord Abbett’s experienced investment team, the fund seeks to capitalize on innovation, demographic changes, and advancements within global health care industries. A distinguishing feature of this fund is its commitment to specialization: approximately 96% of its assets are allocated to health care holdings, with a small balance in repurchase agreements. The fund typically holds around 61 securities, providing both sector concentration and diversified exposure within health care. Designed for institutional investors, the Class R5 share class is structured with a lower net expense ratio relative to other share classes, potentially enhancing cost efficiency for larger organizations. With significant assets under management and a portfolio turnover rate that reflects an active approach, the Lord Abbett Health Care Fund Class R5 plays a critical role for investors seeking targeted participation in health care industry growth, making it a relevant vehicle in sector-based investment strategies.
Performance
LHCTX had a total return of 33.33% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.42%.
Top 10 Holdings
38.34% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.06% |
| AstraZeneca PLC | AZN | 4.82% |
| Gilead Sciences, Inc. | GILD | 4.33% |
| Johnson & Johnson | JNJ | 3.25% |
| Nektar Therapeutics | NKTR | 3.23% |
| Natera, Inc. | NTRA | 2.97% |
| Tarsus Pharmaceuticals, Inc. | TARS | 2.88% |
| Guardant Health, Inc. | GH | 2.68% |
| argenx SE | ARGX | 2.61% |
| Novartis AG | NOVN | 2.52% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 2, 2025 | $0.0847 | Dec 2, 2025 |
| Nov 26, 2024 | $0.1101 | Nov 26, 2024 |
| Nov 22, 2022 | $0.0233 | Nov 22, 2022 |
| Nov 23, 2021 | $1.4724 | Nov 23, 2021 |
| Nov 24, 2020 | $2.3182 | Nov 24, 2020 |
| Nov 21, 2019 | $0.0069 | Nov 21, 2019 |